IBBQ vs WDNA

IBBQAInvesco Nasdaq Biotechnology ETF

WDNACWisdomTree BioRevolution Fund

In short

IBBQ The broad Nasdaq biotech benchmark, bought cheap. IBBQ tracks the whole listed biotech and pharma field, roughly 300 names, for 0.19% a year, well under half the typical fee in its category.

WDNA Most biotech funds stop at drug developers. WDNA follows biology out of the clinic and into food, materials and industrial chemistry, tracking a WisdomTree index shaped with futurist Jamie Metzl.

Stated mandate

IBBQ The Fund tracks the Nasdaq Biotechnology Index and normally invests at least 90% of its assets in index constituents. The index covers Nasdaq-listed companies classified as biotechnology or pharmaceutical companies.

WDNA The Fund seeks to track the WisdomTree BioRevolution Index before fees and expenses. It uses a passive representative-sampling approach to gain global equity exposure to companies expected to be significantly transformed by advances in genetics and biotechnology.

Why people hold it

• IBBQ At 0.19% a year, the lowest fee among its closest biotech rivals and less than half the category median.
• Holds roughly 300 Nasdaq-listed biotech and pharma companies, so one failed trial or one blockbuster is a slice of the fund, not the whole story.invesco.com
• Rules first: normally at least 90% of assets sit in Nasdaq Biotechnology Index constituents. No manager guessing which pipeline pays off.invesco.com
• Stands in the top quartile of the biotech and genomics funds we grade, keeping company with far larger rivals like XBI and IBB.

• WDNA Wider map than a pipeline fund: the index sorts companies across human health, agriculture and food, materials/chemicals/energy, and biological machines and interfaces.wisdomtree.com
• The 0.45% expense ratio sits under the median for genomics and biotech thematics, which is unusual for a niche with this much research behind the index.
• Passive and global by design: roughly 100 listed names worldwide, sampled to track the WisdomTree BioRevolution Index rather than picked by a manager.wisdomtree.com

Worth knowing

• IBBQ Thinly traded next to the category's giants, so bid-ask spreads can widen. Limit orders matter more here than in a heavily traded fund.
• One sector, and a jumpy one: biotech and pharma prices move on trial data and regulatory decisions, a rougher ride than a broad-market fund.invesco.com
• Launched in 2021, so a shorter live record and a smaller asset base than the category's long-standing funds.

• WDNA A small, thinly traded fund. Spreads can run wider than the category heavyweights, so the price you get may drift from the value of what you own.
• For plain biotech exposure, bigger peers cost less: IBBQ at 0.19% and XBI at 0.35%. You pay WDNA's fee for the broader multi-sector definition.
• The issuer flags the theme's own hazards: intense competition, fast product obsolescence, intellectual-property loss, and shifting government rules.wisdomtree.com

Full IBBQ profile⁠

Full WDNA profile⁠